For research use only. Not for therapeutic Use.
A-4250（Cat No.:I000257）(also known as Odevixibat) is a potent, selective ileal bile acid transporter (IBAT) inhibitor used for the treatment of progressive familial intrahepatic cholestasis (PFIC) and other cholestatic liver diseases. By inhibiting IBAT, A-4250 reduces the reabsorption of bile acids in the intestines, leading to decreased bile acid accumulation in the liver and circulation. This alleviates liver damage and reduces symptoms such as severe itching (pruritus) associated with cholestasis. A-4250 offers a novel, non-surgical approach to managing rare pediatric liver disorders, improving patient outcomes and quality of life.
| Catalog Number | I000257 |
| CAS Number | 501692-44-0 |
| Synonyms | A-4250; A4250; A 4250;(S)-2-((R)-2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid |
| Molecular Formula | C37H48N4O8S2 |
| Purity | 98% |
| Target | Apical Sodium-Dependent Bile Acid Transporter |
| Target Protein | Q12908 |
| Solubility | Soluble in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | IC50: IBAT |
| IUPAC Name | (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1λ6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid |
| InChI | InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1 |
| InChIKey | XULSCZPZVQIMFM-IPZQJPLYSA-N |
| SMILES | CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC |
| Reference | <br /> |
